Mitral regurgitation (MR) is the most prevalent valvular heart disease and, when left
untreated, it confers a poorer prognosis. Catheter-based repair therapies face some …

Minimally invasive strategies to treat valvular heart disease have emerged over the past 2
decades. The use of transcatheter aortic valve replacement in the treatment of severe aortic …

In this review, the authors describe some of the latest cardiac CT advances in the evaluation
of cardiovascular disease. This includes automated coronary plaque quantification and …

Mitral annular calcification (MAC) is a common clinical finding and is associated with
adverse clinical outcomes, but the clinical impact of MAC-related mitral valve (MV) …

The use of bioprosthetic valves for treating patients with severe valve disease has increased
over the last 2 decades, and, as a consequence, a growing number of patients with failing …

Over the past decade, transcatheter mitral valve replacement (TMVR) technologies have
evolved with the objective of improving outcomes for patients with severe mitral regurgitation …

The diagnosis and management of mitral and tricuspid valve disease have undergone major
changes in the last few years. The expansion of transcatheter interventions and widespread …

Mitral regurgitation is the second-most frequent valvular heart disease in Europe and it is
associated with high morbidity and mortality. Recognition of MR should encourage the …

Research performed in Europe has driven cardiovascular device innovation. This includes,
but is not limited to, percutaneous coronary intervention, cardiac imaging, transcatheter …

Mitral annular calcium (MAC) with severe mitral valvular dysfunction presents a complex
problem, as valve replacement, either surgical or transcatheter, is challenging because of …